Симуляция графика K-линий, фактические данные указаны на торговой странице
Ключевые данные
Открытие вчера
$17.39
Пред. закрытие
$22.39
Вчерашний диапазон
$17.07 - $22.65
Диапазон 52 нед.
$10.00 - $29.65
Объем торговли
4.998M
МС
$1.288B
P/E
--
EPS
$-1.32
Обзор компании
NASDAQ
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and markets various products for people with insulin-dependent diabetes in the United States. The company is headquartered in San Diego, California.
СекторHEALTHCARE
ОтрасльMEDICAL DEVICES
Штаб-квартира12400 HIGH BLUFF DRIVE, SAN DIEGO, CA, UNITED STATES, 92130
Tandem Diabetes Care is a medical device company that specializes in the design, development, and commercialization of innovative diabetes management systems. Its flagship products include insulin pumps and related technologies to help individuals with diabetes manage blood sugar levels effectively.
Tandem Diabetes Care operates in the healthcare sector, specifically within the medical devices industry. The company focuses on creating advanced technology solutions for people living with diabetes.
Tandem Diabetes Care generates revenue primarily from the sale of its insulin pumps, continuous glucose monitoring accessories, and software subscriptions for its diabetes management solutions. The company also brings in revenue from training and customer support services.
No, Tandem Diabetes Care does not currently pay dividends. The company prioritizes reinvesting earnings into research and development and expanding its business, which is typical for growth-oriented companies in the medical device industry.
Investing in Tandem Diabetes Care involves risks such as competitive pressures in the diabetes management market, regulatory challenges, and reliance on continued innovation and technological advancements. Additionally, the company’s financial performance may be impacted by changes in insurance policies and market demand.
Tandem Diabetes Care faces competition from companies such as Medtronic, Insulet Corporation, and Dexcom Inc., which also produce insulin pumps, continuous glucose monitoring systems, and other diabetes management technologies.
Tandem Diabetes Care focuses on expanding its product portfolio, increasing global market penetration, and enhancing its technological capabilities. Key areas of growth include partnerships with continuous glucose monitoring companies, international expansion, and advancements in artificial intelligence for diabetes care.
TNDM’s valuation metrics, such as its price-to-earnings (P/E) ratio, vary based on market conditions and financial results. Investors often monitor trends in revenue growth, gross margins, and the adoption of new products to assess the company’s performance. Additionally, quarterly earnings reports provide insight into its operational progress and profitability.
Предупреждение о рисках
1.Цены на акции могут сильно колебаться, инвестируйте осторожно. Прошлые результаты не гарантируют будущую доходность.
2.Торговля цифровыми активами сопряжена с рыночными, техническими и иными рисками. Пожалуйста, принимайте взвешенные решения и рационально распределяйте активы.
3.Информация на этой странице предназначена только для ознакомления и не является инвестиционной рекомендацией.